[Expression and prognostic value of vacuole membrane protein 1 in non-small-cell lung cancer].
To investigate the expression and prognostic value of vacuole membrane protein 1 (VMP1) in non-small-cell lung cancer (NSCLC). The clinical data and survival status of 78 NSCLC patients were collected. Their paraffin-embedded tissues were detected immunohistochemically with a custom-made rabbit anti-human VMP1 polyclonal antibody. And the clinical significance of VMP1 expression and its relationship with the overall survival rate were analyzed statistically. The positive expression of VMP1 could only be observed in cytoplasm of cancer cells. Among 78 patients, 40 (51.3%) patients were stained VMP1-positive. The positive rate of VMP1 had a correlation with clinical stage (χ(2) = 6.829, P < 0.05), but not with gender, age, pathological type, gross classification and differentiation grade (P > 0.05). The overall 1-and 3-year survival rate was 94.9% and 66.3% respectively. The overall estimated survival time was 37.2 months (95%CI: 33.7 - 40.8). The expression of VMP1 had significant influence on the survival rate (χ(2) = 6.192, P < 0.05). The VMP1-positive patients lived shorter with an estimated survival time of 29.0 months (95%CI: 25.0 - 33.0). VMP1 expression and clinical stage were independent risk factors of influencing the survival rate. The detection of VMP1 in resected NSCLC tumor tissues may be helpful for prognostic prediction. NSCLC patients with VMP1-positive or late clinical stage have a worse prognosis.